Table 2 Ferroptosis inducers that could be radiosensitizer.

Artesunate

Class IV

ROS

These cell lines include the human pancreatic duct epithelial HPDE cell line, human embryonic kidney 293T cell lines, and four pancreatic adenocarcinoma cell lines (Panc-1, COLO357, AsPC-1, and BxPC-3).

Endogenous Fe²⁺ causes the cleavage of endoperoxide bridge, and leads to the generation of ROS

Buthionine sulfoximine (BSO)

Class I

GSH

4T1 cell

Inhibit GSH synthesis

Cisplatin

Class I

GSH

Cell lines include colorectal cancer (HCT116), fibrosarcoma (HT-1080), and non-small cell lung cancer (NSCLC) (A549, NCIH358, NCIH460, and Calu-1)

Inhibit GSH synthesis

Dihydroartemisinin (DHA)

Class IV

ROS

Human hepatocyte cell line HL-7702, human umbilical vein endothelial cells (HUVECs), human laryngeal carcinoma HEP-2, human nasopharyngeal carcinoma cell lines (5-8F, CNE-1, CNE-2, CNE-2Z), and a non-cancerous immortalized nasopharyngeal epithelial cell line NP-69

Endogenous Fe²⁺ causes the cleavage of endoperoxide bridge, and leads to the generation of ROS

Erastin

Class I

SLC7A11

The following human cell lines were used: A549, H460, H1299, and H23 for non-small cell lung cancer; MCF-7 for breast adenocarcinoma; HT-1080 for fibrosarcoma; FLO-1 for esophageal adenocarcinoma; UMRC6 for renal carcinoma; and human embryonic kidney 293 (HEK293T) cells

Inhibit SLC7A11 activity

Ferroptocide

Class IV

Thioredoxin

ES-2 (ovarian cancer) cell line and HCT 116 cell lines

Inhibit thioredoxin

FIN56

Class III

CoQ, GPX4

The following human cell lines were used: A549, H460, H1299, and H23 for non-small cell lung cancer; MCF-7 for breast adenocarcinoma; HT-1080 for fibrosarcoma; FLO-1 for esophageal adenocarcinoma; UMRC6 for renal carcinoma; and human embryonic kidney 293 (HEK293T) cells

Deplete CoQ and degrade GPX4

Imidazole ketone erastin (IKE)

Class I

SLC7A11

The following cell lines are available: SUDHL-5 (female), SUDHL-6 (male), SUDHL-16 (male), HT-1080 (male), DOHH-2 (male), HBL-1 (male), U2932 (female), SUDHL-7 (male), SUDHL-9 (male), A4/FUK (female), WSU-NHL (female), Ly18 (OCI-Ly18) (male), Karpas422 (female), SUDHL-1 (male), SUDHL-2 (female), SUDHL-8 (male), SUDHL-10 (male), A3/KAW (female), RIVA (female), Ly9 (OCI-Ly9) (male), U937 (male), and Ly7 (OCI-Ly7) (male)

Inhibit SLC7A11 activity

ML162

Class II

GPX4

The following human cell lines were used: A549, H460, H1299, and H23 for non-small cell lung cancer; MCF-7 for breast adenocarcinoma; HT-1080 for fibrosarcoma; FLO-1 for esophageal adenocarcinoma; UMRC6 for renal carcinoma; and human embryonic kidney 293 (HEK293T) cells

Inhibit GPX4 activity

Nonthermal plasma

Class IV

ROS

Human lung cancer cell lines, Calu-1, H1299, H1975, HCC827, A549 and PC9 cells

Promote the release of Fe²⁺ from ferritin

RSL3, (1S,3R)-RSL3

Class II

GPX4

The following human cell lines were used: A549, H460, H1299, and H23 for non-small cell lung cancer; MCF-7 for breast adenocarcinoma; HT-1080 for fibrosarcoma; FLO-1 for esophageal adenocarcinoma; UMRC6 for renal carcinoma; and human embryonic kidney 293 (HEK293T) cells

Inhibit GPX4 activity

Salazosulfapyridine

Class I

SLC7A11

The following human cell lines were used: A549, H460, H1299, and H23 for non-small cell lung cancer; MCF-7 for breast adenocarcinoma; HT-1080 for fibrosarcoma; FLO-1 for esophageal adenocarcinoma; UMRC6 for renal carcinoma; and human embryonic kidney 293 (HEK293T) cells

Inhibit SLC7A11 activity

Salinomycin

Class IV

ROS

Human osteosarcoma U2OS cell line, human mammary epithelial cell line HMLER CD44high/CD24low cells, ICSCL-10A2 cells

Inhibit iron translocation and deplete ferritin

Sorafenib

Class I

SLC7A11

BJeH, BJeHLT, BJeLR, 143B, HT-1080 and Calu-1 cell lines

Inhibit SLC7A11 activity

Withaferin A

Class II

GPX4

IMR-32, SK-N-SH, Kelly, NB69, CHP-134, SH-EP, SH-SY5Y, SK-N-AS, SK-N-DZ, CHP-212 etc. cells

Inhibit GPX4 activity